X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs AUROBINDO PHARMA - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS AUROBINDO PHARMA NOVARTIS/
AUROBINDO PHARMA
 
P/E (TTM) x 472.9 13.8 3,439.1% View Chart
P/BV x 27.4 3.0 918.3% View Chart
Dividend Yield % 1.7 0.4 397.6%  

Financials

 NOVARTIS   AUROBINDO PHARMA
EQUITY SHARE DATA
    NOVARTIS
Mar-18
AUROBINDO PHARMA
Mar-18
NOVARTIS/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs758809 93.7%   
Low Rs579504 114.9%   
Sales per share (Unadj.) Rs228.4281.1 81.3%  
Earnings per share (Unadj.) Rs31.741.4 76.7%  
Cash flow per share (Unadj.) Rs32.850.9 64.4%  
Dividends per share (Unadj.) Rs10.002.50 400.0%  
Dividend yield (eoy) %1.50.4 392.8%  
Book value per share (Unadj.) Rs297.1199.4 149.0%  
Shares outstanding (eoy) m24.69585.88 4.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.92.3 125.3%   
Avg P/E ratio x21.115.9 132.7%  
P/CF ratio (eoy) x20.412.9 158.1%  
Price / Book Value ratio x2.23.3 68.3%  
Dividend payout %31.56.0 521.2%   
Avg Mkt Cap Rs m16,505384,630 4.3%   
No. of employees `0000.717.3 3.9%   
Total wages/salary Rs m1,44521,308 6.8%   
Avg. sales/employee Rs Th8,441.39,500.7 88.8%   
Avg. wages/employee Rs Th2,163.61,229.4 176.0%   
Avg. net profit/employee Rs Th1,173.11,397.9 83.9%   
INCOME DATA
Net Sales Rs m5,639164,666 3.4%  
Other income Rs m1,7181,020 168.5%   
Total revenues Rs m7,357165,686 4.4%   
Gross profit Rs m-6337,718 -0.2%  
Depreciation Rs m255,580 0.5%   
Interest Rs m55777 7.1%   
Profit before tax Rs m1,57532,380 4.9%   
Minority Interest Rs m031 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7928,183 9.7%   
Profit after tax Rs m78424,229 3.2%  
Gross profit margin %-1.122.9 -4.8%  
Effective tax rate %50.325.3 198.9%   
Net profit margin %13.914.7 94.4%  
BALANCE SHEET DATA
Current assets Rs m9,522121,878 7.8%   
Current liabilities Rs m3,29686,806 3.8%   
Net working cap to sales %110.421.3 518.4%  
Current ratio x2.91.4 205.8%  
Inventory Days Days37130 28.2%  
Debtors Days Days2868 41.6%  
Net fixed assets Rs m4681,037 0.1%   
Share capital Rs m123586 21.1%   
"Free" reserves Rs m7,213116,218 6.2%   
Net worth Rs m7,336116,804 6.3%   
Long term debt Rs m04,512 0.0%   
Total assets Rs m11,105211,052 5.3%  
Interest coverage x29.542.7 69.1%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.50.8 65.1%   
Return on assets %7.611.8 63.8%  
Return on equity %10.720.7 51.5%  
Return on capital %22.227.4 81.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m6180,727 0.1%   
Fx outflow Rs m3,63034,700 10.5%   
Net fx Rs m-3,57046,027 -7.8%   
CASH FLOW
From Operations Rs m1,61019,548 8.2%  
From Investments Rs m687-19,570 -3.5%  
From Financial Activity Rs m-2,6778,642 -31.0%  
Net Cashflow Rs m-3808,922 -4.3%  

Share Holding

Indian Promoters % 0.0 54.1 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 8.0 25.2%  
FIIs % 1.6 27.7 5.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 10.2 210.8%  
Shareholders   41,647 69,601 59.8%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   PFIZER  ABBOTT INDIA  PLETHICO PHARMA  WYETH LTD  TORRENT PHARMA  

Compare NOVARTIS With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; Realty and Metal Stocks Lag(09:30 am)

Asian share markets are lower today as Chinese and Hong Kong shares fall. The Shanghai Composite is off 0.1% while the Hang Seng is flat.

Related Views on News

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

The Perfect Stock in the Rebirth of India(The 5 Minute Wrapup)

Aug 8, 2019

This debt-free, well-managed company is all set to soar.

This 60-Year Old Smallcap Company Could Be Our Next Recommendation(The 5 Minute Wrapup)

Aug 12, 2019

My experience at the recent AGM of this smallcap company which has financials of any FMCG major.

Super investor Pulak Prasad is Buying Stocks Big Time...and You Should Too(The 5 Minute Wrapup)

Aug 9, 2019

Here's why the relentless correction in the Indian stock markets has not unnerved the big investors.

Smallcaps that Will Outperform in the Market Rebound(Profit Hunter)

Aug 12, 2019

Only These Smallcaps Will Give Historic Returns in the Future.

Qatar is Rearing Cows...this is Good News for India

Aug 9, 2019

Qatar has turned around after the Saudi embargo. This is good news for India.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Aug 21, 2019 11:03 AM

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - TTK HEALTHCARE COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS